Arcus Biosciences
@arcusbio
Followers
514
Following
20
Media
121
Statuses
153
At the forefront of designing novel combination medicines in the pursuit of cures for people living with cancer. View our guidelines: https://t.co/mP1hLQyMnD
Hayward, CA
Joined January 2017
The first combination data for our HIF-2a inhibitor for the treatment of #KidneyCancer were presented today in an oral session at #ASCO25. Read more about the data and our rapidly advancing development program for casdatifan:
0
1
5
We’re reporting our first-quarter financial results and an update on our clinical-stage pipeline.
0
0
1
First combination data for casdatifan, our HIF-2a inhibitor for the treatment of metastatic #KidneyCancer, will be presented in an oral session at the #ASCO25 Annual Meeting. Read more about this news:
0
1
2
We're reporting our fourth-quarter and full-year financial results as well as an update on our clinical-stage pipeline:
0
0
1
Today we announced that Arcus will retain the rights to casdatifan, our potential best-in-class HIF-2a inhibitor for the treatment of #kidneycancer, and shared pricing of $150 million common stock offering. Read the news here:
0
1
1
New clinical data for casdatifan were presented today in a rapid oral session at ASCO #GU25. These data support the potential for our investigational molecule casdatifan to be a best-in-class HIF-2a inhibitor to treat #kidneycancer. Read about the data:
0
2
3
New clinical data for casdatifan, our HIF-2a inhibitor for the treatment of metastatic #kidneycancer will be presented in a rapid oral session this Saturday at the ASCO #GU25 Symposium. Read more about this news:
0
1
1
We are thrilled to welcome Richard Markus, M.D., Ph.D., to the Arcus team as chief medical officer. He will oversee our clinical development organization and its late-stage portfolio.
0
0
0
We’re reporting our third-quarter financial results and an update on our clinical-stage pipeline.
0
0
1
Today we announced the first overall survival results for the combination of investigational molecules domvanalimab and zimberelimab in #lungcancer. These data will be presented at #SITC24 this week. Read here:
0
2
5
The first overall survival results to be reported for the combination of domvanalimab and zimberelimab in #lungcancer will be presented in a late-breaking poster at @sitcancer. Read about this news and other data we’ll be presenting: #SITC24
0
0
2
RT @MaverickNY: As Arcus chase Merck's belzutifan in the HIF-2α space, can casdatifan live up to its preclinical promise and translate some….
0
3
0
The first clinical data for casdatifan were presented today in an oral plenary session at #ENASymp24. These data support the potential for our investigational molecule casdatifan to be a best-in-class HIF-2a inhibitor to treat #kidneycancer. Read here:
0
0
4
The first clinical data for casdatifan, our HIF-2a inhibitor for the treatment of #kidneycancer will be presented in an oral plenary session at #ENASymp24. Read more about this news and the posters we’ll be presenting:
1
2
4
Today we announced a clinical trial collaboration with @AstraZeneca, representing part of Arcus’s development strategy to pursue a 1st-line differentiated combination of investigational molecule casdatifan for the treatment of #kidneycancer. Read more:
0
2
5
Today we announced that Arcus obtained a term loan facility from Herucles Capital, adding operational flexibility and funding to advance our potential best-in-class HIF-2a inhibitor for the treatment of #kidneycancer. Read more about this news
0
0
2
We're reporting our second-quarter financial results and an update on our clinical-stage pipeline.
0
0
3